Literature DB >> 28194534

The impact of physician-level drug budgets on prescribing behavior.

Katharina Elisabeth Fischer1,2, Taika Koch3, Karel Kostev4, Tom Stargardt3.   

Abstract

To contain pharmaceutical spending, drug budgets have been introduced across health systems. Apart from analyzing whether drug budgets fulfill their overall goal of reducing spending, changes in the cost and quality of prescribing and the enforcement mechanisms put in place need evaluation to assess the effectiveness of drug budgets at the physician level. In this study, we aim to analyze the cost and quality of prescribing conditional on the level of utilization of the drug budget and in view of varying levels of enforcement in cases of overspending. We observed drug budget utilization in a panel of 440 physicians in three federal states of Germany from 2005 to 2011. At the physician level, we retrospectively calculated drug budgets, the level of drug budget utilization, and differentiated by varying levels of enforcement where physicians overspent their budgets (i.e., more than 115/125% of the drug budget). Using lagged dependent-variable regression models, we analyzed whether the level of drug budget utilization in the previous year affected current prescribing in terms of various indicators to describe the cost and quality of prescribing. We controlled for patient and physician characteristics. The mean drug budget utilization is 92.3%. The level of drug budget utilization influences selected dimensions of cost and quality of prescribing (i.e., generic share (estimate 0.000215; p = 0.0246), concentration of generic brands (estimate 0.000585; p = 0.0056) and therapeutic substances (estimate -0.000060; p < 0.0001) and the share of potentially inappropriate medicines in the elderly (estimate 0.001; p < 0.0001)), whereas the level of enforcement does not. Physicians seem to gradually adjust their prescription patterns, especially in terms of generic substitution.

Entities:  

Keywords:  Cost of prescribing; Market regulation; Pharmaceuticals; Physicians

Mesh:

Substances:

Year:  2017        PMID: 28194534     DOI: 10.1007/s10198-017-0875-9

Source DB:  PubMed          Journal:  Eur J Health Econ        ISSN: 1618-7598


  26 in total

Review 1.  The effect of fundholding on prescribing and referral costs: a review of the evidence.

Authors:  T Gosden; D J Torgerson
Journal:  Health Policy       Date:  1997-05       Impact factor: 2.980

2.  [Prescribing behavior of primary care physicians in diabetes therapy: effect of drug budgeting].

Authors:  C Jünger; W Rathmann; G Giani
Journal:  Dtsch Med Wochenschr       Date:  2000-02-04       Impact factor: 0.628

3.  The impact of decentralised drug-budgets in Sweden - a survey of physicians' attitudes towards costs and cost-effectiveness.

Authors:  Sandra Jansson; Anders Anell
Journal:  Health Policy       Date:  2005-07-19       Impact factor: 2.980

Review 4.  Explicit criteria for determining inappropriate medication use in nursing home residents. UCLA Division of Geriatric Medicine.

Authors:  M H Beers; J G Ouslander; I Rollingher; D B Reuben; J Brooks; J C Beck
Journal:  Arch Intern Med       Date:  1991-09

5.  How has fundholding in Northern Ireland affected prescribing patterns? A longitudinal study.

Authors:  T Rafferty; K Wilson-Davis; H McGavock
Journal:  BMJ       Date:  1997-07-19

6.  Preferred supplier contracts in post-patent prescription drug markets.

Authors:  Carl Rudolf Blankart; Tom Stargardt
Journal:  Health Care Manag Sci       Date:  2016-02-22

7.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

Authors:  M E Charlson; P Pompei; K L Ales; C R MacKenzie
Journal:  J Chronic Dis       Date:  1987

8.  Agency and the organization of health care delivery.

Authors:  D Dranove; W D White
Journal:  Inquiry       Date:  1987       Impact factor: 1.730

9.  General practice fundholding: observations on prescribing patterns and costs using the defined daily dose method.

Authors:  M Maxwell; D Heaney; J G Howie; S Noble
Journal:  BMJ       Date:  1993-11-06

Review 10.  Pharmaceutical policies: effects of financial incentives for prescribers.

Authors:  Arash Rashidian; Amir-Houshang Omidvari; Yasaman Vali; Heidrun Sturm; Andrew D Oxman
Journal:  Cochrane Database Syst Rev       Date:  2015-08-04
View more
  3 in total

1.  Exploring the effectiveness of demand-side retail pharmaceutical expenditure reforms : Cross-country evidence from weighted-average least squares estimation.

Authors:  Michael Berger; Markus Pock; Miriam Reiss; Gerald Röhrling; Thomas Czypionka
Journal:  Int J Health Econ Manag       Date:  2022-09-21

Review 2.  The Effectiveness of Interventions to Evaluate and Reduce Healthcare Costs of Potentially Inappropriate Prescriptions among the Older Adults: A Systematic Review.

Authors:  Sara Mucherino; Manuela Casula; Federica Galimberti; Ilaria Guarino; Elena Olmastroni; Elena Tragni; Valentina Orlando; Enrica Menditto
Journal:  Int J Environ Res Public Health       Date:  2022-05-31       Impact factor: 4.614

3.  Physician-Level Cost Control Measures and Regional Variation of Biosimilar Utilization in Germany.

Authors:  Katharina E Blankart; Friederike Arndt
Journal:  Int J Environ Res Public Health       Date:  2020-06-09       Impact factor: 3.390

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.